Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents

NCT06575738 · Recruiting

Last updated 2026-05-28

This clinical trial will observe how adolescents undergoing weight-loss surgery respond physiologically and whether adding the medication semaglutide affects these responses.

Status Recruiting Currently enrolling participants.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 40 people Planned (estimated).

Who can join Ages 12–24 · all sexes

Timeline Started 2024-10 · est. completion 2027-10

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06575738 ↗

Description as written by the study sponsor.

The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond weight loss alone. The study also plans to learn more about whether a medication (semaglutide) can help people 12 to 24 years old who, between 1 and 2 years after bariatric surgery, have not lost as much weight as expected.

Treatments tested

Injectable semaglutide Drug

Subcutaneous weekly injectable semaglutide
Standard postoperative care Behavioral

Standard postoperative care consists of behaviorally-focused interventions delivered by the interdisciplinary Bariatric Surgery Center team targeting nutrition, physical activity, sleep, and mental health at standard postoperative intervals.

Main thing measured	Observational phase: Change in fasting glucagon-like peptide-1 (GLP1), measured by blood levels
Sponsor	University of Colorado, Denver
Conditions studied	Obesity, Adolescent Obesity, Body-Weight Trajectory, Weight Loss Trajectory, Bariatric Surgery, Anti-obesity Agents
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06575738 ↗